Shandong Weigao Medical Polymer Co. (SHWGF)
(Delayed Data from OTC)
$0.96 USD
0.00 (0.00%)
Updated Dec 15, 2023 01:02 PM ET
3-Hold of 5 3
B Value C Growth NA Momentum NA VGM
Income Statements
Fiscal Year end for Shandong Weigao Medical Polymer Co falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 2,024 | 2,039 | 1,644 | 1,500 |
Cost Of Goods | NA | 967 | 912 | 708 | 558 |
Gross Profit | NA | 1,057 | 1,127 | 936 | 941 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 542 | 671 | 544 | 568 |
Income After Depreciation & Amortization | 0 | 515 | 456 | 391 | 373 |
Non-Operating Income | NA | 6 | 7 | -4 | 9 |
Interest Expense | NA | 28 | 22 | 26 | 57 |
Pretax Income | NA | 493 | 440 | 362 | 325 |
Income Taxes | NA | 63 | 64 | 50 | 47 |
Minority Interest | NA | 25 | 28 | 17 | 11 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 430 | 376 | 312 | 278 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 405 | 348 | 294 | 267 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 635 | 568 | 491 | 462 |
Depreciation & Amortization (Cash Flow) | NA | 119 | 112 | 100 | 88 |
Income After Depreciation & Amortization | 0 | 515 | 456 | 391 | 373 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 4,538.85 | 4,516.32 | 4,511.42 | 4,499.72 |
Diluted EPS Before Non-Recurring Items | NA | 0.09 | 0.08 | 0.07 | 0.06 |
Diluted Net EPS (GAAP) | NA | 0.09 | 0.08 | 0.07 | 0.06 |
Fiscal Year end for Shandong Weigao Medical Polymer Co falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |